SOTIO is a biotechnology company developing a new Active Cellular Immunotherapy (“ACI”) based on activated dendritic cells for the treatment of cancer and autoimmune diseases. SOTIO continues to develop new therapies to address unmet medical needs using its immunotherapy platform and proprietary cell-based technologies.

Job Opportunities

The company is looking for talented, motivated, dynamic employees to join its international team, who will have the opportunity to utilize and further develop their own abilities.

SOTIO Presents its Clinical Development Program at the 2016 American Society for Clinical Oncology (ASCO) Annual Meeting

SOTIO, a biotechnology company owned by the PPF Group, presents its clinical development program...